Activity of menin inhibitor ziftomenib (KO-539) as monotherapy or in combinations against AML cells with MLL1 rearrangement or mutant NPM1.
Warren C FiskusNaval G DaverSteffen BoettcherChristopher P MillKoiji SasakiChristine E BirdwellJohn A DavisKaberi DasKoichi TakahashiTapan Mahendra KadiaCourtney D D DiNardoFrancis BurrowsSanam LoghaviJoseph D KhouryBenjamin L EbertKapil N BhallaPublished in: Leukemia (2022)